{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:49:06Z","timestamp":1789624146088,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant immunotherapy (nIO) followed by\u00a0a therapeutic lymph node dissection (TLND) for patients with clinically node-positive melanoma is supported by level 1 evidence. Our aim was to\u00a0assess the association of pathologic response (PR) and nIO regimen with survival among patients with clinical stage III melanoma undergoing nIO and TLND.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Our study included patients treated with nIO followed by a TLND from a large academic institution between 2016 and 2024. The pathologic response was assessed using established guidelines. Differences in extent of PR by nIO regimen were examined. Disease-free survival (DFS) and overall survival (OS) by PR and nIO regimen were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 121 patients (78.5% treated with combination nIO; 21.5% treated with single-agent anti-PD-1). The pCR rate was 64.2% for combination therapy and 53.8% for monotherapy (\n                      <jats:italic>P<\/jats:italic>\n                      =0.11). In univariable analysis, patients who received combination therapy had a\u00a02-year DFS similar to patients treated with single-agent anti-PD-1 (86.5% vs 85.1%, respectively;\n                      <jats:italic>P<\/jats:italic>\n                      =0.43). Patients with a pCR had a 2-year DFS of 94.4% versus 57.3% among those with pathologic non-response (pNR) (\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.001). In multivariable analysis, PR was associated with DFS, but the nIO regimen was not. Our findings showed similar results for OS, with a 2-year OS of 98.1% for patients with pCR compared with 94.7% for those with pNR (\n                      <jats:italic>P<\/jats:italic>\n                      =0.01).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Consistent with clinical trial data, the findings in this study support PR as a strong predictor of survival in this patient population. Studies investigating the de-escalation of surgical and systemic treatment based on PR as well as biomarkers of patients who can achieve a pCR after monotherapy alone are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19130-1","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:24:03Z","timestamp":1773674643000},"page":"6700-6708","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Outcomes for Patients with Clinically Node-Positive Melanoma Undergoing Neoadjuvant Immunotherapy and Nodal Dissection"],"prefix":"10.1245","volume":"33","author":[{"given":"Joshua","family":"Herb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland L.","family":"Bassett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Torres-Cabala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor G.","family":"Prieto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sapna P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Holder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Lucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Wargo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodabe N.","family":"Amaria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella C.","family":"Glitza Oliva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"Tawbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"McQuade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra P.","family":"Ikeguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adi K.","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Gershenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merrick I.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roi","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"19130_CR1","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/S1470-2045(20)30494-0","volume":"21","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Del Vecchio M, Mandal\u00e1 M, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB\u2013C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21:1465\u201377. https:\/\/doi.org\/10.1016\/S1470-2045(20)30494-0.","journal-title":"Lancet Oncol."},{"key":"19130_CR2","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","volume":"12","author":"KF Grossmann","year":"2022","unstructured":"Grossmann KF, Othus M, Patel SP, et al. Adjuvant pembrolizumab versus IFN\u03b12b or Ipilimumab in resected high-risk melanoma. Cancer Discov. 2022;12:644\u201353. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-1141.","journal-title":"Cancer Discov."},{"key":"19130_CR3","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1200\/JCO.20.02110","volume":"38","author":"AMM Eggermont","year":"2020","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG\/KEYNOTE-054 trial. J Clin Oncol. 2020;38:3925\u201336. https:\/\/doi.org\/10.1200\/JCO.20.02110.","journal-title":"J Clin Oncol."},{"key":"19130_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","volume":"27","author":"AM Menzies","year":"2021","unstructured":"Menzies AM, Amaria RN, Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27:301\u20139. https:\/\/doi.org\/10.1038\/s41591-020-01188-3.","journal-title":"Nat Med."},{"key":"19130_CR5","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1.Neoadjuvant","volume":"24","author":"RN Amaria","year":"2018","unstructured":"Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24:1649\u201354. https:\/\/doi.org\/10.1038\/s41591-018-0197-1.Neoadjuvant.","journal-title":"Nat Med."},{"key":"19130_CR6","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/nejmoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, et al. Neoadjuvant\u2013adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323. https:\/\/doi.org\/10.1056\/nejmoa2211437.","journal-title":"N Engl J Med."},{"key":"19130_CR7","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2402604","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/nejmoa2402604.","journal-title":"N Engl J Med."},{"key":"19130_CR8","unstructured":"National comprehensive cancer network clinical practice guidelines in oncology, melanoma: cutaneous v2.2024. Published online 2024:ME-6. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf."},{"key":"19130_CR9","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28:1178\u201388. https:\/\/doi.org\/10.1038\/s41591-022-01851-x.","journal-title":"Nat Med."},{"key":"19130_CR10","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20:948\u201360. https:\/\/doi.org\/10.1016\/S1470-2045(19)30151-2.","journal-title":"Lancet Oncol."},{"key":"19130_CR11","doi-asserted-by":"publisher","first-page":"vii54","DOI":"10.1093\/rheumatology\/key109","volume":"57","author":"S Monti","year":"2018","unstructured":"Monti S, Grosso V, Todoerti M, Caporali R. Randomized controlled trials and real-world data: differences and similarities to untangle literature data. Rheumatol Oxf. 2018;57:vii54\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/key109.","journal-title":"Rheumatol Oxf."},{"key":"19130_CR12","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29:1861\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdy226.","journal-title":"Ann Oncol."},{"key":"19130_CR13","doi-asserted-by":"publisher","first-page":"S1288","DOI":"10.1016\/j.annonc.2023.10.042","volume":"34","author":"S Patel","year":"2023","unstructured":"Patel S, Othus M, Wright P, et al. LBA48 pathologic response and exploratory analyses of neoadjuvant-adjuvant versus adjuvant pembrolizumab (PEM) for resectable stage IIIb-IV melanoma from SWOG S1801. Ann Oncol. 2023;34:S1288. https:\/\/doi.org\/10.1016\/j.annonc.2023.10.042.","journal-title":"Ann Oncol."},{"key":"19130_CR14","doi-asserted-by":"publisher","first-page":"S1715","DOI":"10.1016\/j.annonc.2025.09.069","volume":"36","author":"M Lucas","year":"2025","unstructured":"Lucas M, Menzies A, Dimitriadis P, et al. LBA57 two-year clinical update and first biomarker analyses of the phase 3 NADINA trial comparing neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in resectable stage III melanoma. Ann Oncol. 2025;36:S1715\u20136.","journal-title":"Ann Oncol."},{"key":"19130_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","volume":"157","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Rawson RV, Colebatch AJ, et al. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma. JAMA Surg. 2022;157:335\u201342. https:\/\/doi.org\/10.1001\/jamasurg.2021.7554.","journal-title":"JAMA Surg."}],"updated-by":[{"DOI":"10.1245\/s10434-026-19737-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000}}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19130-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19130-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T15:52:28Z","timestamp":1780761148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19130-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":15,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["19130"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19130-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1245\/s10434-026-19737-4","URL":"https:\/\/doi.org\/10.1245\/s10434-026-19737-4","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Roland L. Bassett was supported in part by an NIH\/NCI Cancer Center Support grant (P30 CA016672). Sapna P. Patel reports institutional funding from 7 Hills, Immatics, Ionctura, Iovance, Linnaeus, and Replimune; consulting support from Daiichi Sankyo, IO Biotech, MSD, Natera, Novartis, Obsidian, Pfizer, Replimune, Scancell, TriSalus Life Sciences, and Veda trials. Ashley M. Holder had grant support from the American College of Surgeons Clowes Award and the Department of Defense CDMRP Melanoma Academy Scholar Program. Rodabe N. Amaria had trial support from Obsidian, KSQ, Regeneron, Immatics, Erasca, and OnKure. Michael A. Davies: was supported\u00a0by the\u00a0Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, the AIM at Melanoma Foundation, the NIH\/NCI P50CA221703, the American Cancer Society, and the Melanoma Research Alliance, Cancer Fighters of Houston, the Anne and John Mendelsohn Chair for Cancer Research, and philanthropic contributions to the Melanoma Moon Shots Program of MD Anderson. He also has been a consultant to Replimmune, Nurix, Roche\/Genentech, Array, Pfizer, Novartis, BMS, GSK, Sanofi-Aventis, Vaccinex, Apexigen, Eisai, Iovance, Merck, and ABM Therapeutics, as well as a scientific advisory board member for THERAtRAME. In addition, he has been the PI of research grants to MD Anderson by Roche\/Genentech, GSK, Sanofi-Aventis, Merck, Myriad, Oncothyreon, Pfizer, ABM Therapeutics, and LEAD Pharma. Merrick I. Ross serves as a melanoma advisory board consultant for Merck Inc and has received travel expenses related to this role. Roi Weiser has received grant support by the SWOG\/Hope Foundation Impact Award. Hussein A. Tawbi reports consulting or advisory roles for Bristol Myers Squibb, Merck, Novartis, Medicenna, Iovance, Eisai, Pfizer, Roche, IO Biotech, Krystal Biotech, Immunocore, Regeneron, Corcept Therapeutics, Strand Therapeutics, and T-Kinfe Therapeutics, as well as research funding from Bristol Myers Squibb, Novartis, Dragonfly Therapeutics, GlaxoSmithKline, Merck, and Roche, Regeneron, Dragonfly Therapeutics, Syntrix Adi K. Diab serves as an advisory board member for-Memgen INC and as a consultant for Regeneron. The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}